COMPUESTOS DE INDAZOL 3,5-DISUSTITUIDOS COMO INHIBIDORES DE CINASA DEPENDIENTE DE CICLINA (CDK)

SE REFIERE A COMPUESTOS DE INDAZOL 3,5-DISUSTITUIDOS CON BENZAMIDAZOLES EN POSICION 3 DE FORMULA I DONDE R1, R2, R3 Y R4 SON H, HALO, CIANO, NITRO, TRIFLUOROMETOXI, TRIFLUROMETILO, AZIDO, HIDROXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {5-[3-(4,6-DIFLUORO-1H-BENZOIMIDAZOL-2-IL)-1H-INDAZOL-5-IL]-4-METILPIRIDIN-3-ILMETIL]ETILAMINA Y ETIL{5-[3-(5-FLUORO-1H-BENZOIMIDAZOL-2-IL)-1H-INDAZOL-5-IL]-4-METILPIRIDIN-3-ILMETIL}AMINA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE CINASA DEPENDIENTE DE CICLINA CDK Y MODULAN Y/O INHIBEN LA PROLIFERACION CELULAR TAL COMO LA ACTIVIDAD DE LAS PROTEINAS CINASAS 3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.